

# Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

## Human ULBP-2/5/6 PE-conjugated Antibody

RRID:AB\_2214693

Type: Antibody

---

### Proper Citation

R and D Systems Cat# FAB1298P, RRID:AB\_2214693

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2214693](http://antibodyregistry.org/AB_2214693)

**Proper Citation:** R and D Systems Cat# FAB1298P, RRID:AB\_2214693

**Target Antigen:** ULBP-2/5/6

**Host Organism:** Mouse

**Clonality:** monoclonal

**Comments:** Applications: Flow Cytometry

**Antibody Name:** Human ULBP-2/5/6 PE-conjugated Antibody

**Description:** This monoclonal targets ULBP-2/5/6

**Target Organism:** human

**Clone ID:** 165903

**Antibody ID:** AB\_2214693

**Vendor:** R and D Systems

**Catalog Number:** FAB1298P

**Record Creation Time:** 20250819T233503+0000

**Record Last Update:** 20250820T054718+0000

---

### Ratings and Alerts

No rating or validation information has been found for Human ULBP-2/5/6 PE-conjugated Antibody.

No alerts have been found for Human ULBP-2/5/6 PE-conjugated Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 13 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Yamane K, et al. (2025) ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. International journal of molecular sciences, 26(7).

Wang L, et al. (2025) CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell reports. Medicine, 6(1), 101889.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. Cancer research communications, 5(3), 476.

Teruya Y, et al. (2025) Ectopic ULBP2 Is Associated with Decreased NKG2D Expression in CD8+ T Cells Under T Cell-Modulatory Conditions in a Murine Tumor Model. Cells, 14(12).

He X, et al. (2025) Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor. Trends in biotechnology, 43(7), 1668.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer immunology research, 12(10), 1421.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell reports. Medicine, 5(11), 101827.

Hartmann JA, et al. (2024) Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses. Cell, 187(10), 2393.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine, 110, 105459.

Gerace D, et al. (2023) Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell reports. Medicine, 4(1), 100879.

Chimienti R, et al. (2022) Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I-/- iPSCs for T cell replacement. Cell reports, 40(13), 111423.

Portillo AL, et al. (2021) Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. *iScience*, 24(6), 102619.

Santaguida S, et al. (2017) Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. *Developmental cell*, 41(6), 638.